ArticleFrontiers in surgery2025
Efficacy and safety of epsilon-aminohexanoic acid and tranexamic acid during posterior interbody fusion surgery.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tranexamic acid (TXA) is a proven effective and favored antifibrinolytic hemostatic drug, while epsilon-aminocaproic acid (EACA) has only recently been applied in the field of orthopedics. Few studies compare the efficacy of these two drugs in spinal surgery. We evaluated the hemostatic performance and safety of aminocaproic acid, and explored whether aminocaproic acid can be used as a substitute for TXA during posterior lumbar interbody fusion (PLIF) surgery, providing theoretical support for the flexible selection of hemostatic drugs during spinal surgery. Methods: We conducted retrospective analysis of 180 patients with lumbar disc herniation, lumbar spinal stenosis, and lumbar spondylolisthesis, who had been admitted to the spinal surgery department of the Our hospital or The Sixth Affiliated Hospital of Xinjiang Medical University, between September 2021 and May 2023, and underwent PLIF. According to the types of hemostatic drugs used during the perioperative period, the patients were divided into two groups, namely, the EACA group ( Results: (1) The red blood cell width of the EACA group (43.94 ± 10.56) was significantly higher than that of the TXA group (40.45 ± 12.54), with a statistically significant difference ( Conclusion: There was no significant difference in total blood loss, total red blood cell loss, transfusion volume/rate, postoperative hospitalization time, hospitalization costs, and surgical complications between the intravenous EACA and TXA groups during PLIF surgery. The two groups had similar hemostatic effects and safety outcomes. Therefore, when selecting antifibrinolytic drugs during PLIF surgery, EACA can be considered an alternative to TXA. However, large-scale, multicenter randomized controlled studies are still required to gauge its later-stage efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.